HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

• Status: Recruiting
• Trial end date: 2026-07-31
• Target enrollment: 0
• Participant gender: Male

Summary

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andrei Iagaru; Stanford University
• Treatments: Bombesin; Edetic Acid; Gallium 68 PSMA-11

Criteria

Inclusion Criteria:

• Patients must be at least 18 years of age;

• Patients must be able to provide informed consent;

• Histologically proven low-grade or intermediate-grade prostate cancer (PC)

• Scheduled to undergo targeted local therapy (HDR brachytherapy).

Exclusion Criteria:

• Inability to lie still for the entire imaging time;

• Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);

• Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;

• Metallic implants (contraindicated for MRI).